Date of Award
January 2013
Document Type
Open Access Thesis
Degree Name
Medical Doctor (MD)
Department
Medicine
First Advisor
Peter W. Marks
Second Advisor
Nikolai A. Podoltsev
Subject Area(s)
Oncology
Abstract
Specific aims: This single-center, retrospective study compared overall survival and hospitalization in older patients with acute myeloid leukemia (AML) receiving first-line treatment with standard induction chemotherapy and decitabine therapy.
Methods: Between January 2000 and December 2009, 36 patients at Yale-New Haven Hospital age 65 years and older with newly diagnosed AML received standard induction chemotherapy (n=11), decitabine therapy (n=11), or supportive care only (n=14). Data obtained included baseline characteristics, achievement of remission, overall survival, inpatient and outpatient visits, and early death.
Results: When compared to standard induction chemotherapy, decitabine patients were significantly older (77 vs 69 years, P = .020) yet had a favorable but nonsignificant trend for increased overall survival (9 vs 7 months, P = .192) and spent significantly fewer days in the hospital (30 vs 41 days, P = .047). Supportive care patients were older (84.5 years) and had a median survival of only 0.6 months.
Conclusions: Compared to standard induction chemotherapy, decitabine as first-line therapy for AML in older patients reduced hospitalization and had a similar overall survival.
Recommended Citation
Clarke, William Thomas, "Less Intensive Therapy For Older Aml Patients" (2013). Yale Medicine Thesis Digital Library. 1783.
https://elischolar.library.yale.edu/ymtdl/1783
This Article is Open Access
Comments
This is an Open Access Thesis.